ArticleFrontiers in public health2025
Pharmacy-based non-communicable diseases screening has high potential for reach: lessons from Rwanda.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Catching Up on Mortality, Falling Behind on Disability: A Dynamic Decomposition of the Health-Adjusted Life Expectancy Gap between Higher-Income and Lower-Income Countries.Annals of global health · 2026Article
- The global burden of cardiovascular diseases attributable to high body mass index, 1990-2023.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low and middle-income countries are entering an epidemiological transition where non-communicable diseases (NCDs) increasingly contribute to disease burden. While Rwanda has one of the most robust public health systems in sub-Saharan Africa, rapid urbanization is leading to an emerging middle-class population who are at high risk for NCDs, but who also underutilize preventive care. The Goodlife Access pilot program in Rwanda screened over 9,000 individuals for diabetes, hypertension, and obesity over 18 months for free; 83% of individuals showed abnormal screening results, 90% of whom had no prior diagnosis. Pharmacy-based screenings effectively reached a high-risk, underserved population and highlights the potential of community pharmacies to amplify NCD diagnoses. While one-third of those screened returned for confirmatory testing at the pharmacy, more work is needed to bolster re-engagement, including addressing fear of confirmatory testing and potential medical treatment costs. Given the successful pilot, Goodlife Access is expanding access to NCD screening while incorporating community-based health insurance and user donations to enhance sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.